

Special Issue

Views and Perspectives of Cutaneous Squamous Cell Carcinoma

Message from the Guest Editors

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer after basal cell carcinoma and represents about 20% of nonmelanoma skin cancer. Most cSCCs are treated successfully by surgical excision and have a good prognosis, but about 10% of these cancers show a more aggressive behavior. These cases of locally advanced and metastatic cSCC are associated with a high mortality rate. They are not amenable to local surgery or radiotherapy and require systemic therapy. In this Special Issue, we aim to compile papers addressing the importance of cSCC in public health regarding epidemiological aspects, prevention, and medical care. We are pleased to invite you to submit original research studies or reviews outlining future demands of cSCC management, which may also include your personal views and opinions. Research areas may include (but are not limited to) the following: epidemiology, risk factors, precancerous lesions, oncogenic mechanisms, diagnosis, and strategies for treatment and prevention of cSCC. We look forward to receiving your contributions.

Guest Editors

Dr. Thomas Meyer

Department of Dermatology St. Josef Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791 Bochum, Germany

Dr. Alexandra Geusau

Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

Deadline for manuscript submissions

closed (30 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/98094

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)